Search clinical trials for: Daunorubicin,Ara-Cytarabine, azacitidine

Total 763 results

National Cancer Institute (NCI)

Not yet recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
Zhongnan Hospital
Shanxi Province Cancer Hospital; Ruijin Hospital; The First Affiliated Hospital... and other collaborators

Recruiting

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukaemia

China
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy
National Cancer Institute (NCI)

Not yet recruiting

MyeloMATCH MSRP: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study

Acute Myeloid Leukemia | Myelodysplastic Syndrome
M.D. Anderson Cancer Center

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals

Recruiting

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Acute Myeloid Leukemia | Myeloid Neoplasm

United States
Pfizer

Completed

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019)

Leukemia, Myeloid, Acute

United States, Spain, Canada, Israel, Korea, Republic of, Taiwan, France, Australia, Germany, Mexico, Japan, Sweden, China, Austria, Belgium, Czechia, Hungary, Italy, Poland, Romania, Russian Federation, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditions

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Refractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent Disease

United States
The First Affiliated Hospital of Soochow University

Recruiting

VA vs DA for Newly Diagnosed Hig-risk AML

Acute Myeloid Leukemia

China
Roswell Park Cancer Institute
Jazz Pharmaceuticals

Recruiting

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations

United States
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals

Terminated

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid Neoplasm

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Acute Myeloid Leukemia | Measurable Disease

China
Massachusetts General Hospital
AbbVie

Recruiting

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated Cells

United States
Beijing 302 Hospital

Not yet recruiting

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Minimal Residual Disease | Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center

Recruiting

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Multilineage Dysplasia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States, Canada
Shenzhen Second People's Hospital

Recruiting

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

China
National Cancer Institute (NCI)

Not yet recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Incyte Corporation; Jazz Pharmaceuticals

Recruiting

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Secondary Acute Myeloid Leukemia | Myeloproliferative Neoplasm

United States
Polish Adult Leukemia Group

Recruiting

A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old (PALG-AML1/2016)

Acute Myeloid Leukemia

United States, Poland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute... and other conditions

United States
Jonsson Comprehensive Cancer Center
University of California, Los Angeles; Pfizer; Jazz Pharmaceuticals

Terminated

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
Karolinska University Hospital
Celgene Corporation

Terminated

Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML

Acute Myeloid Leukemia

Sweden
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Leukemia, Myeloid, Acute

United States, Germany, Italy, France, Australia, Spain, United Kingdom
Cooperative Study Group A for Hematology

Unknown

Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) (AIvsAD)

Acute Myelogenous Leukemia

Korea, Republic of
National Cancer Institute (NCI)

Completed

Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment (ERASE)

Leukemia, Myeloid, Acute
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Acute Myeloid Leukemia | Leukemia | AML

United States
Pfizer

Completed

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Acute Myeloid Leukemia

Japan
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

High-risk (Secondary) Acute Myeloid Leukemia

China
National Cancer Institute (NCI)

Terminated

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Acute Myeloid Leukemia

United States
Jazz Pharmaceuticals
The Leukemia and Lymphoma Society

Completed

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

High Risk Acute Myeloid Leukemia

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia

United States
Therapeutic Advances in Childhood Leukemia Consortium
Gateway for Cancer Research

Completed

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Lymphoblastic Leukemia, Acute, Childhood | Myelogenous Leukemia, Acute, Childhood

United States, Canada, Australia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Unknown

Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients

Acute Myeloid Leukemia

China
Chinese PLA General Hospital

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
Acute Leukemia French Association
Assistance Publique - Hôpitaux de Paris

Withdrawn

ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) (ALFA-0703)

Acute Myeloid Leukemia

France

Search clinical trials for: Daunorubicin,Ara-Cytarabine, azacitidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations